Triple Agonist Weight Loss Drugs: Status and Trials
Triple agonist weight loss drugs: where it is in development, what the trials show so far, and when it could reach patients.
Retatrutide: a quick overview
Body weight percentage lost over 80 weeks in people with severe obesity and heart disease (TRIUMPH-3).
Half-life is about 6 days: after 6 d, half is gone. At five half-lives (30 d), about 3% is left.
Sources: prnewswire.com, europepmc.org.